[CAS NO. 207572-68-7]  Rilmenidine hemifumarate

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [207572-68-7]

Catalog
HY-100490A
Brand
MCE
CAS
207572-68-7

DESCRIPTION [207572-68-7]

Overview

MDL-
Molecular Weight238.28
Molecular FormulaC10H16N2O.1/2C4H4O4
SMILESO=C(O)/C=C/C(O)=O.C1(NC(C2CC2)C3CC3)=NCCO1.[0.5]

For research use only. We do not sell to patients.

Summary

Rilmenidine hemifumarate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine hemifumarate is an alpha 2-adrenoceptor agonist. Rilmenidine hemifumarate induces autophagy . Rilmenidine hemifumarate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na + /H + antiport. Rilmenidine hemifumarate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells [1] [2] [3] .


In Vitro

Rilmenidine provides antihypertensive efficacy comparable with that of diuretics, beta-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors [1] .
Rilmenidine (25-100 μM; 24 hours) inhibits K562 cell proliferation [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay [2]

Cell Line: K562 cells
Concentration: 25, 50, 100 μM
Incubation Time: 24 hours
Result: Dose-dependently inhibited K562 colony formation.

In Vivo

Rilmenidine-treated N171-82Q mice (i.p.; 4-times a week) displays significant improved forelimb grip strength and all limbs grip strength from 12 to 22 weeks of age [3] .
Rilmenidine decreases levels of mutant huntingtin [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT00892892 University of Erlangen-Nürnberg Medical School
Chronic Kidney Disease|Hypertension
November 2009 Phase 4

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

-20°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)


Solvent & Solubility

In Vitro:

H 2 O : 50 mg/mL ( 209.84 mM ; Need ultrasonic)

DMSO : 10 mg/mL ( 41.97 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.1967 mL 20.9837 mL 41.9674 mL
5 mM 0.8393 mL 4.1967 mL 8.3935 mL
10 mM 0.4197 mL 2.0984 mL 4.1967 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 1 mg/mL (4.20 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: 1 mg/mL (4.20 mM); Suspended solution; Need ultrasonic

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 1 mg/mL (4.20 mM); Clear solution

* All of the co-solvents are available by MCE.